Health Catalyst Inc
$ 1.73
-25.11%
07 Aug - close price
- Market Cap 127,837,000 USD
- Current Price $ 1.73
- High / Low $ 1.87 / 1.66
- Stock P/E N/A
- Book Value 1.87
- EPS -3.68
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -1.03 %
- 52 Week High 3.80
- 52 Week Low 0.96
About
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. The company is headquartered in South Jordan, Utah.
Analyst Target Price
$2.31
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-11 | 2026-03-12 | 2025-11-10 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-09 | 2024-02-22 | 2023-11-02 |
| Reported EPS | -0.08 | 0.02 | 0.08 | 0.06 | -0.08 | 0.01 | 0.04 | 0.07 | 0.12 | 0.05 | 0.02 | 0.03 |
| Estimated EPS | -0.05 | 0.01 | 0.0954 | 0.07 | -0.09 | 0.03 | 0.0764 | 0.09 | 0.08 | 0.03 | -0.01 | -0.01 |
| Surprise | -0.03 | 0.01 | -0.0154 | -0.01 | 0.01 | -0.02 | -0.0364 | -0.02 | 0.04 | 0.02 | 0.03 | 0.04 |
| Surprise Percentage | -60% | 100% | -16.1426% | -14.2857% | 11.1111% | -66.6667% | -47.644% | -22.2222% | 50% | 66.6667% | 300% | 400% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HCAT
2026-08-09 00:09:57
Health Catalyst (NASDAQ:HCAT) reported stronger-than-expected Q2 earnings, with an adjusted EPS of $0.04 and revenue of $70.49 million, surpassing analyst estimates. Despite the beat, the company cut its Q3 and full-year 2026 revenue guidance due to anticipated migration-related churn and costs, leading to a significant 25% drop in stock price. Health Catalyst also completed the divestiture of Vitalware and Med-Metrix for $147 million, using the proceeds to become debt-free.
2026-08-08 10:41:27
Health Catalyst (HCAT) saw its stock price drop by 25% following its Q2 2026 report, despite headline numbers not indicating a collapse. The decline is attributed to investor concerns over a changing margin profile due to the sale of the Vitalware unit, the transition to the Ignite platform, and new guidance. The company's Q2 revenue was US$70.5 million, with an adjusted EBITDA of US$9.9 million, but expectations for full-year adjusted gross margin below 50% and a sharp revenue step-down in Q3 have fueled bearish sentiment.
2026-08-08 04:09:57
Health Catalyst, Inc. recently held its Q2 2026 earnings call, detailing a strategic pivot following the divestiture of its Vitalware business for $147 million. This move allowed the company to repay $160 million in debt and focus on core technology, particularly its 'Project Nexus' strategy. Management anticipates continued revenue headwinds from platform migrations but remains committed to disciplined spending and investments in AI-driven automation and the Ignite interoperability platform.
2026-08-07 16:41:27
Health Catalyst (HCAT) shares fell 23.1% after the company issued a weak third-quarter revenue forecast and lowered its full-year outlook, despite exceeding second-quarter revenue expectations. The reduced guidance overshadowed the company's Q2 performance and indicates significant challenges ahead. This significant drop follows a recent gain attributed to easing geopolitical tensions and AI-driven M&A in the software sector.
2026-08-07 15:41:27
Health Catalyst (HCAT) shares plummeted 24.68% in overnight trading after the company issued lower-than-expected third-quarter revenue guidance, despite exceeding its second-quarter revenue guidance. The healthcare intelligence company reported a 13% year-over-year revenue decline in Q2 but saw adjusted EBITDA increase. Investors reacted negatively to the forward-looking financial outlook.
2026-08-07 15:41:27
Health Catalyst (HCAT) reported Q2 2026 revenue of $70.49 million, exceeding the Zacks Consensus Estimate by 2.33%, despite a 12.7% year-over-year decline. The company's EPS of $0.04 surpassed the consensus estimate of $0.02 by 100%. Key metrics like professional services revenue and adjusted gross profits also largely outperformed analyst expectations.
